SecBot SecBot
SECBOTREPLAY Home › Report › SABS

SABS · SAB Biotherapeutics (SABS) has announced the commencement of an…

SAB Biotherapeutics, Inc. · PRESS-RELEASE filed Mar 17, 2026 at 16:01 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Mar 17, 2026 at 16:01 ET

SAB Biotherapeutics (SABS) has announced the commencement of an underwritten public offering of common stock and pre-funded warrants, with an option for underwriters to purchase up to an additional 15%. The company intends to use the proceeds to fund clinical development of its lead candidate, SAB-142, for type 1 diabetes, along with manufacturing, regulatory activities, and general corporate purposes. The offering is subject to market conditions, and no specific size, price, or terms have been disclosed.

  • SAB Biotherapeutics (SABS) has commenced an underwritten public offering of common stock and pre-funded warrants.
  • Underwriters have a 30-day option to purchase up to an additional 15% of the securities offered.
  • All securities are being sold by the company, indicating dilution for existing shareholders.
  • Proceeds will be used to fund development of SAB-142 through clinical trials, manufacturing, regulatory activities, and general corporate purposes.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access